Table II.
Summary of neuropsychological assessment
| Domain test | Patients (C+; n = 14) | Healthy controls (HC; n = 15) | Impaired patients (IC+; n = 7) | Difference C+ vs. HC (t test or M‐U) | Difference IC+ vs. HC (t test or M‐U) | |||
|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | P value | P value | |
| Attention and concentration | ||||||||
| Attention Bourdon‐Wiersma avg/row (s) | 12.56 | 3.09 | 10.61 | 1.32 | 13.7 | 3.56 | 0.023 | 0.0018 |
| Every day attention—auditory elevator TEA ST5 | 5.44 | 3.58 | 7.86 | 2.21 | 3.2 | 2.91 | 0.015 | 0.0002 |
| Cognitive/psychomotor speed | ||||||||
| Trail making test A (s) | 28.09 | 9.52 | 22.23 | 3.66 | 32.8 | 9.67 | 0.025 | 0.0006 |
| Nine‐hole pegboard, Nondominant hand (s) | 20.26 | 2.73 | 17.94 | 1.31 | 21.1 | 2.65 | 0.004 | 0.0005 |
| WAIS digit symbol | 58.56 | 14.17 | 67.41 | 11.01 | 49.9 | 10.95 | 0.053 | 0.0004 |
| Self reported cognitive complaints: CQF | ||||||||
| Distraction | 11.2 | 4.9 | 9.1 | 2.1 | 12.8 | 4.5 | 0.06 | 0.02 |
| Distraction in social situations | 6.1 | 2.2 | 6.4 | 1.8 | 7.3 | 1.9 | 0.35 | 0.25 |
| Names and words | 4.8 | 2.2 | 5.8 | 2.1 | 4.8 | 2.6 | 0.11 | 0.18 |
| Orientation | 6.2 | 1.5 | 5.7 | 1.5 | 6.8 | 1.9 | 0.22 | 0.06 |
| Total score | 36.7 | 13.6 | 35.2 | 7.5 | 42.0 | 12.3 | 0.35 | 0.09 |
All units are arbitrary, except specified otherwise. C+: chemotherapy‐treated patients; HC: healthy controls; IC: impaired patients, defined as C+ patients having more than two cognitive tests outside normal variance (>2 standard deviation (SD) difference from mean of controls).
Note: Higher scores on TEA‐ST5 and WAIS digit symbol and lower scores on Bourdon‐Wiersma, Nine‐hole Peg and Trail Making Test indicate better performance.